Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Ohio State University | OTHER |
| University of Minnesota | OTHER |
| University of Oklahoma | OTHER |
| The University of Texas Health Science Center, Houston |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
We hypothesize that topical betaxolol will reduce the development of severe retinopathy of prematurity.
The drug is administered twice a day between 32 and 35 weeks gestational age, at a t ime when ROP is most likely to arise.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| betaxolol | Experimental | betaxolol 0.25% 2 per day for 3 weeks |
|
| placebo | Placebo Comparator | masked labeling also 2 per day administration |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Betaxolol | Drug |
| ||
| topical betaxolol |
| Measure | Description | Time Frame |
|---|---|---|
| development of apnea and or bradycardia | babies were monitored and HR/RR monitored and recorded by masked observers, periodically | 3 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| development of ROP requiring treatment | Type I ROP was used as a secondary outcome measure | 7 weeks |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D015784 | Betaxolol |
| ID | Term |
|---|---|
| D050198 | Phenoxypropanolamines |
| D011412 | Propanolamines |
| D000605 | Amino Alcohols |
| D000438 | Alcohols |
Not provided
Not provided
| OTHER |
Not provided
Not provided
Not provided
Not provided
given topically |
|
| D009930 |
| Organic Chemicals |
| D020005 | Propanols |
| D000588 | Amines |